Abstract
Background: Available data show that COVID-19 vaccines may be less effective in immunocompromised populations, who are at increased risk of severe COVID-19.
Objectives: We conducted a systematic review of literature to assess immunogenicity, efficacy and effectiveness of COVID-19 vaccines in immunocompromised populations.
Data sources: We searched Medline and Embase databases.
Study eligibility criteria, patients, interventions: We included studies of COVID-19 vaccines after complete vaccination in immunocompromised patients until 31 August 2021. Studies with <10 patients, safety data only and case series of breakthrough infections were excluded.
Methods: Risk of bias was assessed via the tool developed by the National Institutes of Health on interventional and observational studies. Immunogenicity was assessed through non-response rate defined as no anti-SARS-CoV-2 spike protein antibodies, efficacy and effectiveness by the relative reduction in risk of SARS-CoV-2 infection or COVID-19. We collected factors associated with the risk of non-response. We presented collected data by immunosuppression type.
Results: We screened 5917 results, included 162 studies. There were 157 on immunogenicity in 25 209 participants, including 7835 cancer or haematological malignancy patients (31.1%), 6302 patients on dialysis (25.0%), 5974 solid organ transplant recipients (23.7%) and 4680 immune-mediated disease patients (18.6%). Proportion of non-responders seemed higher among solid organ transplant recipients (range 18-100%) and patients with haematological malignancy (range 14-61%), and lower in patients with cancer (range 2-36%) and patients on dialysis (range 2-30%). Risk factors for non-response included older age, use of corticosteroids, immunosuppressive or anti-CD20 agent. Ten studies evaluated immunogenicity of an additional dose. Five studies evaluated vaccine efficacy or effectiveness: three on SARS-CoV-2 infection (range 71-81%), one on COVID-19-related hospitalization (62.9%), one had a too small sample size.
Conclusions: This systematic review highlights the risk of low immunogenicity of COVID-19 vaccines in immunocompromised populations, especially solid organ transplant recipients and patients with haematological malignancy. Despite lack of vaccine effectiveness data, enhanced vaccine regimens may be necessary.
Keywords: COVID-19; Cancer; Dialysis; Effectiveness; Efficacy; Immunogenicity; SARS-CoV-2 immunocompromised; Solid organ transplant; Vaccine.
【저자키워드】 COVID-19, Efficacy, Vaccine, immunogenicity, Cancer, dialysis, Effectiveness, solid organ transplant, SARS-CoV-2 immunocompromised, 【초록키워드】 antibodies, SARS-CoV-2, Vaccine, COVID-19 vaccine, vaccination, severe COVID-19, Hospitalization, SARS-COV-2 infection, Immunosuppression, systematic review, risk, anti-SARS-CoV-2, observational studies, Spike protein, Immunocompromised patient, Patient, Older age, Immunocompromised, Breakthrough infection, eligibility criteria, patients, anti-CD20, dose, immunosuppressive, solid organ, malignancy, regimen, Patients with cancer, Factor, Participants, increased risk, collected data, small sample size, recipient, haematological malignancy, Complete, non-responder, populations, effective, immune-mediated disease, highlight, defined, lack, collected, evaluated, conducted, screened, case sery, less, searched, reduction in, patients with haematological, use of corticosteroids, were excluded, 【제목키워드】 COVID-19 vaccine, systematic review, Immunocompromised, Clinical efficacy,